Dexy Susp 60ml

Name: Dexy Susp 60ml
Brand: Reckitt
SKU: HP-05726
Price: 129.00 PKR
Availability: InStock
Rating: 4.0 (25 reviews)

4.0 (25)SKU HP-05726

A suspension containing Dexibuprofen, indicated for Pain & Inflammation.

Rs. 129Rs. 143-10%

You save Rs. 14

100g Cream

In StockSet your city for an exact delivery date

In stock at selected branches

Quantity

100% authentic
Free over Rs. 1,500
Pharmacist verified
7-day returns

Total for 1 pack: Rs. 129

What it is used for: Pain & Inflammation.

Indications as listed by the manufacturer: Dexibuprofen is indicated for: - Symptomatic treatment for the relief of pain and inflammation associated with osteoarthritis. - Acute symptomatic treatment of pain during menstrual bleeding (primary dysmenorrhea). - Symptomatic treatment of mild to moderate pain, such as muscular skeletal pain or dental pain. - It may be used as an antipyretic to reduce fever.

How it works: Dexibuprofen, a racemic ibuprofen belongs to a family of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). Like other NSAIDs, dexibuprofen acts by inhibiting prostaglandin synthesis. It reduces pain, inflammation and fever and reversibly inhibits ADP and collagen stimulated platelet aggregation.

Active ingredient: Dexibuprofen.

Reported side effects: Common : Dyspepsia, diarrhea, nausea, vomiting, abdominal pain, rash, fatigue or drowsiness, headache, dizziness, vertigo, edema and hypertension. Uncommon : Gastrointestinal ulcers and bleeding, ulcerative stomatitis, gastritis, malaena, urticaria, pruritus, purpura (including allergic purpura), angioedema, rhinitis, bronchospasm, insomnia, anxiety, restlessness, visual disturbances and tinnitus. Rare : Gastrointestinal perforation, flatulence, constipation, esophagitis, esophageal strictures, exacerbation of diverticular disease, unspecific hemorrhagic colitis, ulcerative colitis, Crohn's disease, anaphylactic reactions, psychotic reactions, depression, irritability, disorientation, confusion, agitation, reversible toxic amblyopia, impaired hearing, abnormal liver function, hepatitis, jaundice, blood disorders including thrombocytopenia, leucopenia, granulocytopenia, pancytopenia, agranulocytosis, aplastic anemia or hemolytic anemia.

Known drug interactions: Anti-coagulants, such as warfarin , Methotrexate , Lithium , NSAIDs and salicylates , Diuretics , sulphonylurea , Zidovudine (Azidothymidine) , Pemetrexed , Alcohol , Cyclosporine, tacrolimus, sirolimus and aminoglycoside antibiotic , Corticosteroids , Digoxin , Phenytoin, phenobarbital and rifampicin , Thrombolytics, ticlopidine and antiplatelet agents.

Dexibuprofen is contraindicated in patients: - Previously sensitive to dexibuprofen, to any other NSAID, or to any of the excipients of the product. - In whom substances with a similar action (e.g., aspirin or other NSAIDs) precipitate attacks of asthma, bronchospasm, acute rhinitis, or cause nasal polyps, urticaria or angioneurotic edema. - With a history of gastrointestinal bleeding or perforation, related to previous NSAID therapy. - With active, or a history of recurrent peptic ulcer/hemorrhage (two or more distinct episodes of proven ulceration or bleeding). - With cerebrovascular bleeding or other active bleedings. - With active Crohn's disease or active ulcerative colitis. - With severe heart failure. - With severe renal dysfunction (GFR < 30 ml/min). - With severely impaired hepatic function. - From the beginning of 6th month of pregnancy
Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention and edema have been reported in association with NSAID therapy. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with dexibuprofen after careful consideration.
If used in the patients with renal or hepatic disease, the dose of dexibuprofen should be kept as low as possible and renal function should be regularly monitored.
Dexibuprofen should only be given with care to patients with systemic lupus erythematosus and mixed connective tissue disease because such patients may be predisposed to NSAID-induced renal and CNS side effects, including aseptic meningitis.
The use of dexibuprofen with concomitant NSAIDs including cyclooxygenase-2 selective inhibitors should be avoided. Care is recommended in conditions that predispose patients to the gastrointestinal adverse effects of NSAIDs. These patients should be closely monitored for digestive disturbances, especially gastrointestinal bleeding, perforation & ulceration.

What it is used for: Pain & Inflammation.

Active ingredient: Dexibuprofen.

Dexibuprofen is contraindicated in patients: - Previously sensitive to dexibuprofen, to any other NSAID, or to any of the excipients of the product. - In whom substances with a similar action (e.g., aspirin or other NSAIDs) precipitate attacks of asthma, bronchospasm, acute rhinitis, or cause nasal polyps, urticaria or angioneurotic edema. - With a history of gastrointestinal bleeding or perforation, related to previous NSAID therapy. - With active, or a history of recurrent peptic ulcer/hemorrhage (two or more distinct episodes of proven ulceration or bleeding). - With cerebrovascular bleeding or other active bleedings. - With active Crohn's disease or active ulcerative colitis. - With severe heart failure. - With severe renal dysfunction (GFR < 30 ml/min). - With severely impaired hepatic function. - From the beginning of 6th month of pregnancy
Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention and edema have been reported in association with NSAID therapy. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with dexibuprofen after careful consideration.
If used in the patients with renal or hepatic disease, the dose of dexibuprofen should be kept as low as possible and renal function should be regularly monitored.
Dexibuprofen should only be given with care to patients with systemic lupus erythematosus and mixed connective tissue disease because such patients may be predisposed to NSAID-induced renal and CNS side effects, including aseptic meningitis.
The use of dexibuprofen with concomitant NSAIDs including cyclooxygenase-2 selective inhibitors should be avoided. Care is recommended in conditions that predispose patients to the gastrointestinal adverse effects of NSAIDs. These patients should be closely monitored for digestive disturbances, especially gastrointestinal bleeding, perforation & ulceration.